Show simple item record

dc.contributor.authorVesala, Renata
dc.contributor.authorElenjord, Renate
dc.contributor.authorLehnbom, Elin
dc.contributor.authorOfstad, Eirik Hugaas
dc.contributor.authorJohnsgård, Tine
dc.contributor.authorZahl-Holmstad, Birgitte
dc.contributor.authorRisør, Torstein
dc.contributor.authorWisløff, Torbjørn
dc.contributor.authorRøslie, Lars
dc.contributor.authorFilseth, Ole Magnus
dc.contributor.authorValle, Per Christian
dc.contributor.authorSvendsen, Kristian
dc.contributor.authorFrøyshov, Hanne Mathilde
dc.contributor.authorGarcia, Beate Hennie
dc.date.accessioned2022-02-02T09:51:09Z
dc.date.available2022-02-02T09:51:09Z
dc.date.issued2021-11-25
dc.description.abstractIntroduction - The ‘emergency department (ED) pharmacist’ is an integrated part of the ED interdisciplinary team in many countries, which have shown to improve medication safety and reduce costs related to hospitalisations. In Norway, few EDs are equipped with ED pharmacists, and research describing effects on patients has not been conducted. The aim of this study is to investigate the impact of introducing clinical pharmacists to the interdisciplinary ED team. In this multicentre study, the intervention will be pragmatically implemented in the regular operation of three EDs in Northern Norway; Tromsø, Bodø and Harstad. Clinical pharmacists will work as an integrated part of the ED team, providing pharmaceutical care services such as medication reconciliation, review and/or counselling. The primary endpoint is ‘time in hospital during 30 days after admission to the ED’, combining (1) time in ED, (2) time in hospital (if hospitalised) and (3) time in ED and/or hospital if re-hospitalised during 30 days after admission. Secondary endpoints include time to rehospitalisation, length of stay in ED and hospital and rehospitalisation and mortality rates.<p> <p>Methods and analysis - We will apply a non-randomised stepped-wedge study design, where we in a staggered way implement the ED pharmacists in all three EDs after a 3, 6 and 9 months control period, respectively. We will include all patients going through the three EDs during the 12-month study period. Patient data will be collected retrospectively from national data registries, the hospital system and from patient records.<p> <p>Ethics and dissemination - The Regional Committee for Medical and Health Research Ethics and Local Patient Protection Officers in all hospitals have approved the study. Patients will be informed about the ongoing study on a general basis with ads on posters and flyers.en_US
dc.identifier.citationVesala, Elenjord, Lehnbom, Ofstad, Johnsgård, Zahl-Holmstad, Risør, Wisløff, Røslie, Filseth, Valle, Svendsen, Frøyshov, Garcia. Integrating the clinical pharmacist into the emergency department interdisciplinary team: a study protocol for a multicentre trial applying a non-randomised stepped-wedge study design. BMJ Open. 2021en_US
dc.identifier.cristinIDFRIDAID 1983967
dc.identifier.doi10.1136/bmjopen-2021-049645
dc.identifier.issn2044-6055
dc.identifier.urihttps://hdl.handle.net/10037/23891
dc.language.isoengen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.journalBMJ Open
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
dc.titleIntegrating the clinical pharmacist into the emergency department interdisciplinary team: a study protocol for a multicentre trial applying a non-randomised stepped-wedge study designen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record